EGFR and non-small cell lung carcinoma: Tivantinib (ARQ 197; ArQule, Inc., Woburn, MA), a MET TKI 58, is being evaluated in combination with erlotinib in a phase 3 trial in Asian patients with wild-type EGFR advanced NSCLC (ATTENTION; NCT01377376).